GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Myriad Genetics Inc (STU:MYD) » Definitions » 3-Year Revenue Growth Rate

Myriad Genetics (STU:MYD) 3-Year Revenue Growth Rate : 1.90% (As of Mar. 2024)


View and export this data going back to 1995. Start your Free Trial

What is Myriad Genetics 3-Year Revenue Growth Rate?

Myriad Genetics's Revenue per Share for the three months ended in Mar. 2024 was €2.07.

During the past 12 months, Myriad Genetics's average Revenue per Share Growth Rate was 6.10% per year. During the past 3 years, the average Revenue per Share Growth Rate was 1.90% per year. During the past 5 years, the average Revenue per Share Growth Rate was -4.10% per year. During the past 10 years, the average Revenue per Share Growth Rate was -0.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

During the past 13 years, the highest 3-Year average Revenue per Share Growth Rate of Myriad Genetics was 45.70% per year. The lowest was -9.10% per year. And the median was 16.70% per year.

Competitive Comparison of Myriad Genetics's 3-Year Revenue Growth Rate

For the Diagnostics & Research subindustry, Myriad Genetics's 3-Year Revenue Growth Rate, along with its competitors' market caps and 3-Year Revenue Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Myriad Genetics's 3-Year Revenue Growth Rate Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Myriad Genetics's 3-Year Revenue Growth Rate distribution charts can be found below:

* The bar in red indicates where Myriad Genetics's 3-Year Revenue Growth Rate falls into.


Myriad Genetics 3-Year Revenue Growth Rate Calculation

This is the 3-year average growth rate of Revenue per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

Myriad Genetics  (STU:MYD) 3-Year Revenue Growth Rate Explanation

Revenue per Share is the amount of Revenue per outstanding share of the company's stock.

Revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top. Revenue per share growth rate is used in calculating Predictability Rank, companies with more consistent revenue and earnings growth are ranked high with predictability.

Myriad Genetics 3-Year Revenue Growth Rate Related Terms

Thank you for viewing the detailed overview of Myriad Genetics's 3-Year Revenue Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Myriad Genetics (STU:MYD) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Myriad Genetics Inc (STU:MYD) » Definitions » 3-Year Revenue Growth Rate
Comparable Companies
NEO TWST VCYT NEOG GH SHC OPK LAB CDNA CSTL TMO DHR A IDXX IQV XSWX:LONN MTD ICLR WAT ILMN
Traded in Other Exchanges
MYGN:USA MYD:Germany
Address
320 Wakara Way, Salt Lake City, UT, USA, 84108
Website
https://www.myriad.com
Myriad Genetics is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel with the capability to identify the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm offers biomarker discovery and companion diagnostic services to pharma and biotech companies.